CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Novavax Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Novavax Inc
700 Quince Orchard Road
Phone: (240) 268-2000p:240 268-2000 GAITHERSBURG, MD  20878  United States Ticker: NVAXNVAX
Business Summary
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Margaret G.Mcglynn 65 3/10/2025 12/7/2020
President, Chief Executive Officer, Director John C.Jacobs 58 1/23/2023 1/23/2023
Chief Financial Officer, Executive Vice President, Treasurer James P.Kelly 59 8/16/2021 8/16/2021
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Novavax AB (OLD) Kungsgatan, 109 UPPSALA Sweden

Business Names
Business Name
14 Firstfield Holdings, LLC
Novavax AB
Novavax CH GmbH
9 additional Business Names available in full report.

General Information
Number of Employees: 952 (As of 12/31/2024)
Outstanding Shares: 162,421,645 (As of 7/31/2025)
Shareholders: 177
Stock Exchange: NASD
Federal Tax Id: 222816046
Fax Number: (302) 636-5454
Email Address: nox@novavax.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, August 15, 2025